Related Experiment Videos
Gluten-free diet--what is toxic?
Paul J Ciclitira1, H Julia Ellis, Knut E A Lundin
1Gastroenterology, Rayne Institute (KCL) St Thomas' Hospital, Lambeth Palace Road, SE1 7EH London, UK. paul.ciclitira@kcl.ac.uk
Best Practice & Research. Clinical Gastroenterology
|June 1, 2005
Summary
The cornerstone of coeliac disease treatment is a strict gluten-free diet. Research is exploring specific gluten peptides and individual patient responses to identify safe gluten intake levels and potential new therapies.
Area of Science:
- Gastroenterology
- Immunology
- Dietary Science
Background:
- Coeliac disease (CD) management relies on a strict gluten-free diet (GFD).
- Oats are generally tolerated but can elicit responses in some CD patients.
- Individual variability in clinical and mucosal responses to gluten challenge is significant.
Purpose of the Study:
- To investigate the toxicity of specific gluten peptides in coeliac disease.
- To understand the relationship between identified toxic peptides and T-cell epitopes.
- To clarify the clinical significance of these epitopes and determine safe gluten intake levels for CD patients.
Main Methods:
- In vitro and in vivo testing of synthetic gluten peptides.
- Analysis of T-cell recognition of gluten epitopes.
- Assessment of clinical and mucosal responses to gluten challenge.
Main Results:
- Identification of synthetic gluten peptides toxic to the coeliac small intestinal mucosa.
- Partial overlap between toxic peptide toxicity and T-cell recognised epitopes.
- Unclear clinical significance of several identified epitopes.
Conclusions:
- Further research is needed to understand the precise mechanisms of gluten toxicity in coeliac disease.
- Determining a safe maximum gluten intake level for coeliac patients remains a challenge.
- Future studies may lead to improved therapeutic strategies for coeliac disease.